The news of JP Morgan maintaining an Overweight rating on Thermo Fisher Scientific (TMO) and lowering the price target from $675 to $660 may not have a significant short-term impact on the stock price. The lowered price target still indicates a positive outlook for the company, but investors may have already priced in the analyst's opinion. The relevance and importance of this news are high, as it directly pertains to TMO and its valuation. However, the short-term price direction remains neutral, as the market may have already factored in the analyst's views.